Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 10.30M | $867.0M | 13.76% | +8.74M | 2026-03-31 |
| FMR LLC | 9.26M | $779.0M | 12.37% | +1.04M | 2026-03-31 |
| VR ADVISER, LLC | 8.49M | $714.0M | 11.34% | -- | 2026-03-31 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.38M | $368.0M | 5.84% | -370.9K | 2026-03-31 |
| BlackRock, Inc. | 4.09M | $343.0M | 5.46% | +301.7K | 2026-03-31 |
| RTW INVESTMENTS, LP | 2.78M | $234.0M | 3.72% | +70.0K | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.50M | $210.0M | 3.34% | -- | 2026-03-31 |
| JANUS HENDERSON GROUP PLC | 2.36M | $198.0M | 3.15% | +298.0K | 2026-03-31 |
| STATE STREET CORP | 2.16M | $182.0M | 2.89% | +472.8K | 2026-03-31 |
| Driehaus Capital Management LLC | 1.92M | $161.0M | 2.57% | -- | 2026-03-31 |
